Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Topline data were announced from a phase 3 trial evaluating CagriSema in overweight or obese patients without type 2 diabetes.

Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly ...

RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just ...

Metsera Announces Positive Topline Phase 2a Clinical Data for its Ultra-Long Acting GLP-1 Receptor Agonist, MET-097i ...

For the first time in a decade, body mass index and obesity prevalence in adults declined in the United States in 2023.

There are now more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

In a world grappling with obesity and chronic disease, GLP-1 drugs like Ozempic are emerging as transformative game-changers. Initially designed for diabetes, these medications now promise ...

CagriSema, for example, targets both GLP-1RA and an amylin receptor agonist (this mimics the hormone amylin, which regulates blood glucose levels) while Retatrutide targets three receptors — GLP-1RA, ...

GLP-1 receptor agonist weight loss drugs can negatively interact with eating disorder psychopathology and treatment in ...

If a person decides to start GLP-1RA treatment, careful monitoring is essential to quickly identify any worsening of eating disorder behaviors, such as the development of extreme dietary ...